Navigation Links
Targeted prostate biopsy has potential to improve diagnosis of prostate cancer
Date:12/10/2012

New York, NY, December 10, 2012 Diagnosis of prostate cancer remains imperfect. Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers. Investigators at the University of California-Los Angeles Department of Urology have found that a new technique of targeted biopsy in a clinic setting, using local anesthesia, may improve diagnosis and aid in selecting which patients are suitable for active surveillance and which need focal therapy (noninvasive techniques for destroying small tumors within the prostate). Their results are published in The Journal of Urology.

"The technology exists to biopsy prostate tumors under magnetic resonance imaging (MRI) guidance and this has been shown to improve prostate cancer diagnosis," says first author Geoffrey Sonn, MD, Department of Urology, Institute of Urologic Oncology, University of California-Los Angeles. "But such procedures are time-consuming, costly, and impractical in most settings. Magnetic resonance ultrasound (MR-US) systems that fuse stored MR images with real-time ultrasound combine the resolution of MRI with the ease and practicality of ultrasound, offering a savings in time and cost, while potentially retaining the accuracy of MR-guided biopsy. However there are further limiting factors the need for monitored anesthesia care, or a transperineal approach and general anesthesia."

Investigators report on the findings in a group of men who underwent MR-US fusion biopsy as outpatients at the UCLA Clark Urology Center. Of the 171 men in the study, 106 underwent biopsy for surveillance, while 65 had an increased prostate specific antigen (PSA) level but previously negative biopsies. All had a median PSA of 4.9 ng/ml and a median prostate size of 48 cc. Following a procedure lasting about 20 minutes, none of the patients required hospitalization.

The researchers found that a targeted biopsy was three times more likely to identify cancer than a systematic biopsy. The biopsies showed prostate cancer in 90 of the 171 men.

"The study yielded three key findings," reports Leonard S. Marks, MD, lead investigator, professor of urology and director of the UCLA Active Surveillance Program. "First, it demonstrated the ability to target and biopsy lesions in an office-based setting with the patient under local anesthesia. Second, adding targeted biopsies to systematic biopsies increased the rate of diagnosis of all cancers and, more importantly, Gleason 7 or greater cancer. In fact, 38% of men with Gleason 7 or greater cancer had disease which was detected only by targeted biopsies of lesions detected on MRI. Third, the level of suspicion on MRI correlates with cancer diagnosis overall and diagnosis of Gleason 7 or greater prostate cancers. The biopsies revealed prostate cancer in 16 of 17 men with a grade 5 lesion on MRI."

The study shows that targeted prostate biopsy may be useful in the three key situations of active surveillance, increased PSA but negative transrectal ultrasound (TRUS) biopsy, and selection for focal therapy. It may improve patient selection, making surveillance a more attractive option for patients while reducing progression to active treatment. It may also identify tumors missed on TRUS biopsy, sparing patients the discomfort of numerous negative biopsies and reducing the risk of delayed diagnosis of aggressive tumors.

"Finally, focal therapy has become an area of keen interest. This technique can spare patients the more invasive, morbid perineal template-mapping biopsy often required for focal therapy. Two recent studies using different MR-US fusion devices yielded similar results. "This substantiates the advantages of image-guided targeted biopsy using MR-US fusion" concludes Dr. Marks.

The investigators acknowledge that due to the low risk patient population studied, relatively few patients underwent radical prostate surgery. "It remains possible that some tumors may be missed by this technique," says Dr. Marks. Further work, including a detailed study correlating MRI, targeted biopsy results, and prostatectomy specimens is ongoing.

Commenting on the study, Dr. Bradford Hood and colleagues at the National Cancer Institute, NIH, write, "MR-US fusion guided biopsy unblinds the 'blind' biopsy and has great potential to supplement or replace 'blind' TRUS prostate biopsies. However, significant hurdles remain to broad adoption and the best approach is yet to be determined."


'/>"/>

Contact: Linda Gruner
jumedia@elsevier.com
212-633-3923
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Targeted Prostate Cancer Biopsies Might Improve Care: Study
2. Researchers report first success of targeted therapy in most common non-small cell lung cancer
3. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
4. Temple researchers show targeted cancer drug may stunt hearts ability to repair itself
5. Large lung cancer study shows potential for more targeted therapies
6. Deadly witch hunts targeted by grassroots womens groups
7. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Lower risk of serious side-effects in trials of new targeted drugs
10. Killer infections targeted by hospital study
11. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: